Glenmark Pharmaceuticals Ltd
GLENMARKGlenmark Pharmaceuticals Ltd
GLENMARKPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-26.77 | 4.09 | 0.18% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast from 11 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 7,581.67 | 9,116.78 | 9,165.82 | 10,240.79 | 10,833.45 | 11,038.69 | 12,471.57 | 13,306.90 | 13,050.42 | 12,914.97 | ||||||||||
Raw Materials | 2,442.74 | 3,073.93 | 2,904.86 | 3,421.01 | 3,570.56 | 3,809.43 | 4,396.42 | 4,862.05 | 11,518.72 | 11,518.72 | ||||||||||
Power & Fuel Cost | 120.47 | 127.02 | 137.48 | 165.26 | 173.69 | 164.67 | 200.64 | 227.52 | ||||||||||||
Employee Cost | 1,378.20 | 1,640.81 | 1,871.84 | 2,056.07 | 2,254.78 | 2,343.71 | 2,447.42 | 2,780.96 | ||||||||||||
Selling & Administrative Expenses | 1,395.79 | 1,589.86 | 1,523.27 | 1,750.21 | 1,667.02 | 1,453.55 | 1,543.27 | 1,790.09 | ||||||||||||
Operating & Other expenses | 787.32 | 692.04 | 1,021.60 | 887.12 | 1,276.84 | 1,088.19 | 1,657.76 | 1,816.98 | ||||||||||||
EBITDA | 1,457.15 | 1,993.12 | 1,706.77 | 1,961.12 | 1,890.56 | 2,179.14 | 2,226.06 | 1,829.30 | 1,531.70 | 1,396.25 | ||||||||||
Depreciation/Amortization | 234.28 | 264.37 | 301.88 | 325.91 | 417.17 | 443.55 | 486.72 | 611.27 | 581.91 | 581.91 | ||||||||||
PBIT | 1,222.87 | 1,728.75 | 1,404.89 | 1,635.21 | 1,473.39 | 1,735.59 | 1,739.34 | 1,218.03 | 949.79 | 814.34 | ||||||||||
Interest & Other Items | 178.89 | 237.32 | 285.57 | 334.59 | 377.32 | 353.11 | 298.10 | 349.58 | 515.97 | 515.97 | ||||||||||
PBT | 1,043.98 | 1,491.43 | 1,119.32 | 1,300.62 | 1,096.07 | 1,382.48 | 1,441.24 | 868.45 | 433.82 | 298.37 | ||||||||||
Taxes & Other Items | 300.94 | 382.67 | 315.46 | 375.63 | 320.11 | 412.44 | 499.54 | 571.21 | 1,935.49 | 1,800.03 | ||||||||||
Net Income | 743.04 | 1,108.76 | 803.86 | 924.99 | 775.96 | 970.04 | 941.70 | 297.24 | -1,501.67 | -1,501.66 | ||||||||||
EPS | 26.85 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | -53.22 | ||||||||||
DPS | 2.00 | 2.00 | 2.00 | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | ||||||||||
Payout ratio | 0.07 | 0.05 | 0.07 | 0.06 | 0.09 | 0.07 | 0.07 | 0.24 | — | -0.05 |
Company Updates
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Glenmark Pharmaceuticals Ltd | -26.77 | 4.09 | 0.18% |
Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare GLENMARK with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Glenmark Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.1939% | Percentage of the fund’s portfolio invested in the stock 1.35% | Change in the portfolio weight of the stock over the last 3 months 0.45% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/76 (+7) |
Aditya Birla Sun Life Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6122% | Percentage of the fund’s portfolio invested in the stock 1.12% | Change in the portfolio weight of the stock over the last 3 months -0.44% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/91 (+18) |
Aditya Birla Sun Life Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3476% | Percentage of the fund’s portfolio invested in the stock 2.41% | Change in the portfolio weight of the stock over the last 3 months 0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 46/95 (-37) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
GLENMARK has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.18%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.75 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 18, 2023
Dividend/Share
₹2.50
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 12, 2022
Dividend/Share
₹2.50
Ex DateEx Date
Sep 12, 2022
Cash Dividend
Ex DateEx DateSep 8, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Dividend/Share
₹2.50
Ex DateEx Date
Sep 17, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Dividend/Share
₹2.00
Ex DateEx Date
Sep 19, 2019
Stock that will see action today: 18 July 2024
Glenmark Pharma receives USFDA approval for seizure treatment drug
USFDA approves Glenmark Pharma’s seizure treatment drug
Glenmark receives USFDA approval for Topiramate Capsules
Glenmark Pharma gets USFDA approval for seizures drug
Glenmark Life Sciences dips on Glenmark Pharma’s plan to exit
Glenmark Life, Pharma in focus: Shares fall up to 4% amid stake sale buzz
Glenmark Pharma Hits All-Time High On Plan To Exit Glenmark Life
Stock that will see action today: 11 July 2024
Stocks to watch, July 11: YES Bank, Glenmark Pharma, Nykaa, SBI, Tata Elxsi
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 4.97%, vs industry avg of 8.96%
Decreasing Market Share
Over the last 5 years, market share decreased from 4.52% to 3.55%